The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels ...

Analyst Trung Huynh from UBS asked about potential ACIP policy changes ... s focus on operational efficiency, capital allocation, and strategic R&D shifts positions Pfizer to navigate ...

Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future success.

Other changes at Pfizer include Mikael Dolsten ... He will also cover business analytics, global commercial operations and patient and health impact, among others. Pfizer’s Consumer Healthcare ...

risks related to the successful integration of the licensed asset with Pfizer’s business; disruption from the transaction making it more difficult to maintain business and operational ...

And the key policy change impacts on Pfizer was a reduced ability to raise ... opportunities to drive improvements in productivity and operational efficiency in our R&D organization, again ...